Table 3.
Cardiovascular events during follow-up
| Overall | Women | Men | P-value | |
|---|---|---|---|---|
| Yearly cardiovascular event-rate (%) (95% CI) | 6.3 (5.2–7.7) | 8.2 (6.0–10.9) | 5.4 (4.1–6.9) | 0.03 |
| Total cardiovascular eventsa, n (%) | 105 (17.1) | 46 (21.8) | 59 (14.6) | 0.03 |
| Death from cardiovascular cause | 20 (3.3) | 9 (4.3) | 11 (2.7) | 0.34 |
| Cardiac arrhythmic death | 7 (1.1) | 4 (1.9) | 3 (0.7) | 0.24 |
| Cardiac non-arrhythmic death | 3 (0.5) | 1 (0.5) | 2 (0.5) | 0.99 |
| Non-cardiac vascular death | 10 (1.6) | 4 (1.9) | 6 (1.5) | 0.74 |
| Heart failure hospitalization | 22 (3.6) | 9 (4.3) | 13 (3.2) | 0.50 |
| Stroke | 15 (2.4) | 5 (2.4) | 10 (2.5) | 0.99 |
| Ischaemic stroke | 11 (1.8) | 4 (1.9) | 7 (1.7) | 0.99 |
| Haemorrhagic stroke | 5 (0.8) | 1 (0.5) | 4 (1.0) | 0.67 |
| Systemic embolism | 1 (0.2) | – | 1 (0.2) | 0.99 |
| Bleeding | 28 (4.6) | 14 (6.6) | 14 (3.5) | 0.10 |
| Intracranial bleeding | 3 (0.5) | 1 (0.5) | 2 (0.5) | 0.99 |
| Extracranial bleedingb | 25 (4.1) | 13 (6.2) | 12 (3.0) | 0.08 |
| Syncope | 6 (1.0) | 4 (1.9) | 2 (0.5) | 0.19 |
| Life-threatening adverse effects of rate control drugs | 5 (0.8) | 3 (1.4) | 2 (0.5) | 0.35 |
| Sustained ventricular tachycardia or ventricular fibrillation | 1 (0.2) | – | 1 (0.2) | 0.99 |
| Implantable cardioverter defibrillation implantation | 1 (0.2) | – | 1 (0.2) | 0.99 |
| Pacemaker implantation | 6 (1.0) | 2 (0.9) | 4 (1.0) | 0.99 |
CI, confidence interval.
a
Includes the total number of cardiovascular events that occurred during follow-up.
b
Extracranial bleeding events in women included: gastrointestinal (n = 4), post-surgery/intervention (n = 3), knee haematoma (n = 2), large haematoma upper leg after trauma (n = 3), retroperitoneal (n = 1). Extracranial bleeding events in men included: gastrointestinal (n = 5), post-surgery/intervention (n = 4), retroperitoneal bleeding (n = 1), urinary tract (n = 1), pulmonary related to bronchus carcinoma (n = 1).